Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA; Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Eur J Surg Oncol. 2024 Sep;50(9):108532. doi: 10.1016/j.ejso.2024.108532. Epub 2024 Jul 3.
Accurate prediction of patients at risk for early recurrence (ER) among patients with colorectal liver metastases (CRLM) following preoperative chemotherapy and hepatectomy remains limited.
Patients with CRLM who received chemotherapy prior to undergoing curative-intent resection between 2000 and 2020 were identified from an international multi-institutional database. Multivariable Cox regression analysis was used to assess clinicopathological factors associated with ER, and an online calculator was developed and validated.
Among 768 patients undergoing preoperative chemotherapy and curative-intent resection, 128 (16.7 %) patients had ER. Multivariable Cox analysis demonstrated that Eastern Cooperative Oncology Group Performance status ≥1 (HR 2.09, 95%CI 1.46-2.98), rectal cancer (HR 1.95, 95%CI 1.35-2.83), lymph node metastases (HR 2.39, 95%CI 1.60-3.56), mutated Kirsten rat sarcoma oncogene status (HR 1.95, 95%CI 1.25-3.02), increase in tumor burden score during chemotherapy (HR 1.51, 95%CI 1.03-2.24), and bilateral metastases (HR 1.94, 95%CI 1.35-2.79) were independent predictors of ER in the preoperative setting. In the postoperative model, in addition to the aforementioned factors, tumor regression grade was associated with higher hazards of ER (HR 1.91, 95%CI 1.32-2.75), while receipt of adjuvant chemotherapy was associated with lower likelihood of ER (HR 0.44, 95%CI 0.30-0.63). The discriminative accuracy of the preoperative (training: c-index: 0.77, 95%CI 0.72-0.81; internal validation: c-index: 0.79, 95%CI 0.75-0.82) and postoperative (training: c-index: 0.79, 95%CI 0.75-0.83; internal validation: c-index: 0.81, 95%CI 0.77-0.84) models was favorable (https://junkawashima.shinyapps.io/CRLMfollwingchemotherapy/).
Patient-, tumor- and treatment-related characteristics in the preoperative and postoperative setting were utilized to develop an online, easy-to-use risk calculator for ER following resection of CRLM.
在接受术前化疗和肝切除的结直肠癌肝转移(CRLM)患者中,准确预测早期复发(ER)的高危患者仍然有限。
从一个国际多机构数据库中确定了 2000 年至 2020 年间接受化疗后接受根治性切除术的 CRLM 患者。使用多变量 Cox 回归分析评估与 ER 相关的临床病理因素,并开发和验证了在线计算器。
在 768 例接受术前化疗和根治性切除术的患者中,128 例(16.7%)患者发生 ER。多变量 Cox 分析表明,东部合作肿瘤组表现状态≥1(HR 2.09,95%CI 1.46-2.98)、直肠癌(HR 1.95,95%CI 1.35-2.83)、淋巴结转移(HR 2.39,95%CI 1.60-3.56)、突变 Kirsten 大鼠肉瘤致癌基因状态(HR 1.95,95%CI 1.25-3.02)、化疗期间肿瘤负荷评分增加(HR 1.51,95%CI 1.03-2.24)和双侧转移(HR 1.94,95%CI 1.35-2.79)是术前 ER 的独立预测因素。在术后模型中,除上述因素外,肿瘤消退分级与 ER 更高的危害相关(HR 1.91,95%CI 1.32-2.75),而接受辅助化疗与 ER 可能性降低相关(HR 0.44,95%CI 0.30-0.63)。术前(训练:c 指数:0.77,95%CI 0.72-0.81;内部验证:c 指数:0.79,95%CI 0.75-0.82)和术后(训练:c 指数:0.79,95%CI 0.75-0.83;内部验证:c 指数:0.81,95%CI 0.77-0.84)模型的判别准确性均较好(https://junkawashima.shinyapps.io/CRLMfollwingchemotherapy/)。
利用术前和术后患者、肿瘤和治疗相关特征,开发了一种用于预测 CRLM 切除后 ER 的在线易用风险计算器。